Sign in
Active, not recruitingPhase 2

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Key facts

Who runs it
Brown University
Where
Providence, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
184 people, planned
Started
19 Aug 2019
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Doxazosin
  • Placebo
Record updated
23 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Male or female, 18 years of age
  • Meet the DSM-5 criteria for AUD
  • Desire to reduce or quit alcohol drinking
  • Breath alcohol (BrAC) = 0.00 at each visit
  • In good health as confirmed by medical history, physical examination and lab tests
  • Willing to adhere to the study procedures
  • Understand informed consent and questionnaires in English at an 8th grade level

Who cannot take part

  • Current use of medication that may interact with doxazosin and/or yohimbine
  • Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening
  • Treatment with any alpha-blocker
  • Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication
  • Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline
  • History of allergy to any alpha receptor blockers
  • Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG
  • Women who are breastfeeding or /positive urine test for pregnancy
  • CrCl<60mL/min
  • Suicide attempt in the last three months
  • Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8
  • Baseline hypotension defined as BP reading lower than 90/60 mmHg

Where in United States

  • Brown UniversityProvidence, United States

About the trial

What the trial wants to find out

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

The 2 groups in the trial

  • doxazosinTreatment being tested

    16 mg, or maximum tolerated dose (MTD)

  • placeboPlacebo, for comparison

    matching placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD
Record updated
23 September 2026